Weekly cyclophosphamide and alternate-day prednisone

An effective secondary therapy in multiple myeloma

K. Wilson, W. Shelley, A. Belch, L. Brandes, D. Bergsagel, Paul Klimo, D. White, A. Willan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Intravenous or oral cyclophosphamide, 150-250 mg/m2 (500 mg maximum), once per week with alternate-day oral prednisone, 100 mg, was given to 57 myeloma patients resistant to melphalan and prednisone (MP). Seven responses in 28 primary MP-resistant patients and ten responses in 29 secondary MP-resistant patients were observed. Previous response to MP was not a significant factor in predicting response to weekly cyclophosphamide and alternate-day prednisone. The results suggest that the regimen of weekly cyclophosphamide and alternate-day prednisone may be as effective as more aggressive regimens in the treatment of patients with myeloma who have failed MP therapy. However, a randomized trial would be required to determine the relative contributions of cyclophosphamide and prednisone to the effectiveness of this regimen.

Original languageEnglish (US)
Pages (from-to)981-982
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number10
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Prednisone
Multiple Myeloma
Cyclophosphamide
Melphalan
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wilson, K., Shelley, W., Belch, A., Brandes, L., Bergsagel, D., Klimo, P., ... Willan, A. (1987). Weekly cyclophosphamide and alternate-day prednisone: An effective secondary therapy in multiple myeloma. Cancer Treatment Reports, 71(10), 981-982.

Weekly cyclophosphamide and alternate-day prednisone : An effective secondary therapy in multiple myeloma. / Wilson, K.; Shelley, W.; Belch, A.; Brandes, L.; Bergsagel, D.; Klimo, Paul; White, D.; Willan, A.

In: Cancer Treatment Reports, Vol. 71, No. 10, 01.12.1987, p. 981-982.

Research output: Contribution to journalArticle

Wilson, K, Shelley, W, Belch, A, Brandes, L, Bergsagel, D, Klimo, P, White, D & Willan, A 1987, 'Weekly cyclophosphamide and alternate-day prednisone: An effective secondary therapy in multiple myeloma', Cancer Treatment Reports, vol. 71, no. 10, pp. 981-982.
Wilson, K. ; Shelley, W. ; Belch, A. ; Brandes, L. ; Bergsagel, D. ; Klimo, Paul ; White, D. ; Willan, A. / Weekly cyclophosphamide and alternate-day prednisone : An effective secondary therapy in multiple myeloma. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 10. pp. 981-982.
@article{76f01a05159b46a985c11903a4d38d40,
title = "Weekly cyclophosphamide and alternate-day prednisone: An effective secondary therapy in multiple myeloma",
abstract = "Intravenous or oral cyclophosphamide, 150-250 mg/m2 (500 mg maximum), once per week with alternate-day oral prednisone, 100 mg, was given to 57 myeloma patients resistant to melphalan and prednisone (MP). Seven responses in 28 primary MP-resistant patients and ten responses in 29 secondary MP-resistant patients were observed. Previous response to MP was not a significant factor in predicting response to weekly cyclophosphamide and alternate-day prednisone. The results suggest that the regimen of weekly cyclophosphamide and alternate-day prednisone may be as effective as more aggressive regimens in the treatment of patients with myeloma who have failed MP therapy. However, a randomized trial would be required to determine the relative contributions of cyclophosphamide and prednisone to the effectiveness of this regimen.",
author = "K. Wilson and W. Shelley and A. Belch and L. Brandes and D. Bergsagel and Paul Klimo and D. White and A. Willan",
year = "1987",
month = "12",
day = "1",
language = "English (US)",
volume = "71",
pages = "981--982",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Weekly cyclophosphamide and alternate-day prednisone

T2 - An effective secondary therapy in multiple myeloma

AU - Wilson, K.

AU - Shelley, W.

AU - Belch, A.

AU - Brandes, L.

AU - Bergsagel, D.

AU - Klimo, Paul

AU - White, D.

AU - Willan, A.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Intravenous or oral cyclophosphamide, 150-250 mg/m2 (500 mg maximum), once per week with alternate-day oral prednisone, 100 mg, was given to 57 myeloma patients resistant to melphalan and prednisone (MP). Seven responses in 28 primary MP-resistant patients and ten responses in 29 secondary MP-resistant patients were observed. Previous response to MP was not a significant factor in predicting response to weekly cyclophosphamide and alternate-day prednisone. The results suggest that the regimen of weekly cyclophosphamide and alternate-day prednisone may be as effective as more aggressive regimens in the treatment of patients with myeloma who have failed MP therapy. However, a randomized trial would be required to determine the relative contributions of cyclophosphamide and prednisone to the effectiveness of this regimen.

AB - Intravenous or oral cyclophosphamide, 150-250 mg/m2 (500 mg maximum), once per week with alternate-day oral prednisone, 100 mg, was given to 57 myeloma patients resistant to melphalan and prednisone (MP). Seven responses in 28 primary MP-resistant patients and ten responses in 29 secondary MP-resistant patients were observed. Previous response to MP was not a significant factor in predicting response to weekly cyclophosphamide and alternate-day prednisone. The results suggest that the regimen of weekly cyclophosphamide and alternate-day prednisone may be as effective as more aggressive regimens in the treatment of patients with myeloma who have failed MP therapy. However, a randomized trial would be required to determine the relative contributions of cyclophosphamide and prednisone to the effectiveness of this regimen.

UR - http://www.scopus.com/inward/record.url?scp=0023634925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023634925&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 981

EP - 982

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -